Conclusion: However, limited data on long-term safety, optimal dosing strategies, and durability of treatment effects warrant caution. Future research should evaluate extended treatment duration, dose-response relationships, and patient-reported outcomes to establish comprehensive clinical utility.
PubMed 42538058 ↗Tesamorelin
The short answer. More people than not who report on Tesamorelin say it helped (58% of 119). It is most often used for weight loss: 95% of 82 reports say that improved. It is well studied — 3 meta-analyses on PubMed. The most common complaint is water retention. It is not an approved supplement and carries real risks.
From 265 mentions in total — the rest didn't say how it went and aren't counted.
What Tesamorelin does, according to users
Of the people who reported each effect, the share who said it got better.
What the research says
Systematic reviews and meta-analyses from PubMed, with their published conclusions.
3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 3 meta-analyses on PubMed ↗ · 21 randomized trials ↗
Conclusion: Tesamorelin improves body composition, hepatic fat, lean body mass, and IGF-1 levels in HIV-associated lipodystrophy, without serious side effects or perturbation of glucose.
PubMed 41545261 ↗Conclusion: Our review indicates that, based on the findings of the 10 included studies, GH axis treatments are effective in reducing VAT and increasing LBM in patients with HIV-associated lipodystrophy. However, clinicians must decide whether the attributed benefits are clinically significant, considering the costs and potential risks of GH axis treatments. A limitation of this study is the small number of studies available of each GH axis drug class.
PubMed 21265979 ↗24 human trials on ClinicalTrials.gov test Tesamorelin — 14 completed, 3 recruiting now. See all on ClinicalTrials.gov ↗
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons · Mild Cognitive Impairment · 2023
- Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk · Non-Alcoholic Fatty Liver Disease, Obesity · 2025
- TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy · Lipodystrophy, HIV Infections · 2008
What government agencies say
Official records from US, Canadian and EU regulators, each linked to its source.
LiverTox rates Tesamorelin E — an unlikely cause of liver injury. LiverTox entry ↗
NIH has funded 3 research projects with Tesamorelin in the title, $8,154,641 in total (2015–2026). NIH RePORTER ↗
Dosage people report
Reported side effects
How often each side effect came up across all reports.
What users say
First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.
“I also added Tesamorelin 2 months in due to the harder time sleeping on Retatrutide and wanting to accelerate the burn of my visceral fats (2mg 5x a week). Worked like magic for me.”
“I now have my tesa early morning still fasted from Monday to Friday. My Reta Friday mornings as well. No tesa or Reta on weekends, and found my sleep improved dramatically.”
“Did a quick Reta run, then slowed that down and started the GH journey. And it has been great. I feel a lot stronger and my endurance has boosted!”
“I had my bloodwork done while taking Tesa. Never had any result like that.”
Tesamorelin compared
Other options for weight loss
Sources
- User reports: 265 mentions in public discussions, quoted with a link to each discussion (e.g. this thread ↗).
- PubMed (US National Library of Medicine, NIH): meta-analyses ↗ · randomized trials ↗
- ClinicalTrials.gov (NIH): registered trials ↗
- LiverTox (NIH) ↗
- NIH RePORTER ↗
User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate